Literature DB >> 8500309

How many stratification factors are "too many" to use in a randomization plan?

T M Therneau1.   

Abstract

The issue of stratification and its role in patient assignment has generated much discussion, mostly focused on its importance to a study or lack thereof. This report focuses on a much narrower problem: assuming that stratified assignment is desired, how many factors can be accommodated? This problem is investigated for two methods of balanced patient assignments; the first is based on the minimization method of Taves and the second on the commonly used method of stratified assignment. Simulation results show that the former method can accommodate a large number of factors (10-20) without difficulty but that the latter begins to fail if the total number of distinct combination of factor levels is greater than approximately n/2. The two methods are related to a linear discriminant model, which helps to explain the results.

Entities:  

Mesh:

Year:  1993        PMID: 8500309     DOI: 10.1016/0197-2456(93)90013-4

Source DB:  PubMed          Journal:  Control Clin Trials        ISSN: 0197-2456


  28 in total

1.  Comparison of balanced and random allocation in clinical trials: a simulation study.

Authors:  M M Rovers; H Straatman; G A Zielhuis
Journal:  Eur J Epidemiol       Date:  2000       Impact factor: 8.082

2.  Second-order interactions with the treatment groups in controlled clinical trials.

Authors:  Shyang-Yun Pamela K Shiao; Chul W Ahn; Kouhei Akazawa
Journal:  Comput Methods Programs Biomed       Date:  2007-02-14       Impact factor: 5.428

3.  Issues in outcomes research: an overview of randomization techniques for clinical trials.

Authors:  Minsoo Kang; Brian G Ragan; Jae-Hyeon Park
Journal:  J Athl Train       Date:  2008 Apr-Jun       Impact factor: 2.860

4.  Challenges and lessons learned in conducting comparative-effectiveness trials.

Authors:  Linda M Herrick; G Richard Locke; Alan R Zinsmeister; Nicholas J Talley
Journal:  Am J Gastroenterol       Date:  2012-05       Impact factor: 10.864

5.  Effect of Amitriptyline and Escitalopram on Functional Dyspepsia: A Multicenter, Randomized Controlled Study.

Authors:  Nicholas J Talley; G Richard Locke; Yuri A Saito; Ann E Almazar; Ernest P Bouras; Colin W Howden; Brian E Lacy; John K DiBaise; Charlene M Prather; Bincy P Abraham; Hashem B El-Serag; Paul Moayyedi; Linda M Herrick; Lawrence A Szarka; Michael Camilleri; Frank A Hamilton; Cathy D Schleck; Katherine E Tilkes; Alan R Zinsmeister
Journal:  Gastroenterology       Date:  2015-04-25       Impact factor: 22.682

6.  Randomization in clinical trials: stratification or minimization? The HERMES free simulation software.

Authors:  Hélène Fron Chabouis; Francis Chabouis; Florence Gillaizeau; Pierre Durieux; Gilles Chatellier; N Dorin Ruse; Jean-Pierre Attal
Journal:  Clin Oral Investig       Date:  2013-03-01       Impact factor: 3.573

7.  A phase III randomized, double-blind, placebo-controlled study of pilocarpine for vaginal dryness: North Central Cancer Treatment group study N04CA.

Authors:  Charles L Loprinzi; Ernie P Balcueva; Heshan Liu; Jeff A Sloan; Lisa A Kottschade; Philip J Stella; Mark D Carlson; Dennis F Moore; Robin T Zon; Ralph Levitt; Anthony J Jaslowski
Journal:  J Support Oncol       Date:  2011 May-Jun

8.  Functional Dyspepsia Treatment Trial (FDTT): a double-blind, randomized, placebo-controlled trial of antidepressants in functional dyspepsia, evaluating symptoms, psychopathology, pathophysiology and pharmacogenetics.

Authors:  Nicholas J Talley; G Richard Locke; Linda M Herrick; Vickie M Silvernail; Charlene M Prather; Brian E Lacy; John K DiBaise; Colin W Howden; Darren M Brenner; Ernest P Bouras; Hashem B El-Serag; Bincy P Abraham; Paul Moayyedi; Alan R Zinsmeister
Journal:  Contemp Clin Trials       Date:  2012-02-10       Impact factor: 2.226

9.  Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1.

Authors:  Charles L Loprinzi; Rui Qin; Ernie P Balcueva; Ernie P Baclueva; Kathleen A Flynn; Kendrith M Rowland; David L Graham; Nancy K Erwin; Shaker R Dakhil; Donald J Jurgens; Kelli N Burger
Journal:  J Clin Oncol       Date:  2009-11-09       Impact factor: 44.544

10.  An evaluation of constrained randomization for the design and analysis of group-randomized trials.

Authors:  Fan Li; Yuliya Lokhnygina; David M Murray; Patrick J Heagerty; Elizabeth R DeLong
Journal:  Stat Med       Date:  2015-11-23       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.